Kestra Medical Technologies (NASDAQ:KMTS) CFO Sells $199,352.37 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 8,817 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $22.61, for a total value of $199,352.37. Following the completion of the transaction, the chief financial officer directly owned 99,282 shares of the company’s stock, valued at approximately $2,244,766.02. This trade represents a 8.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total value of $128,305.80.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total value of $90,545.00.

Kestra Medical Technologies Stock Down 3.4%

Shares of NASDAQ KMTS opened at $25.06 on Thursday. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -10.36 and a beta of 0.58. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 12 month low of $14.10 and a 12 month high of $30.00. The stock has a 50-day moving average price of $22.78 and a two-hundred day moving average price of $22.52.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

KMTS has been the subject of a number of research reports. Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research upped their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Finally, The Goldman Sachs Group lowered their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and a consensus price target of $27.83.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KMTS. Seven Grand Managers LLC bought a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at $2,652,000. Eventide Asset Management LLC raised its stake in Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in Kestra Medical Technologies during the fourth quarter worth $9,282,000. UBS Group AG lifted its holdings in Kestra Medical Technologies by 34.9% in the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after buying an additional 69,908 shares during the period. Finally, Jennison Associates LLC boosted its position in Kestra Medical Technologies by 15.0% during the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after acquiring an additional 28,573 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.